Extended Data Fig. 3: Association between elevated IL-8 level and reduced survival was also seen in the non-immunotherapy trial arms. | Nature Medicine

Extended Data Fig. 3: Association between elevated IL-8 level and reduced survival was also seen in the non-immunotherapy trial arms.

From: Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Extended Data Fig. 3

The specific study, 2-sided log-rank test P values for the survival analysis, the number of independent patients with available IL-8 and OS data (n), and the OS HR (based on Cox proportional hazard model) between IL-8 subgroups (≥23 pg/ml versus <23 pg/ml) are indicated within each chart. a, Probability of OS with <23 pg/ml or ≥23 pg/ml IL-8 levels in patients with RCC treated with everolimus from CheckMate 025 (n = 348). b, Probability of OS with <23 pg/ml or ≥23 pg/ml IL-8 levels in patients with nsqNSCLC treated with docetaxel from CheckMate 057 (n = 253). HR, hazard ratio; IL, interleukin; nsqNSCLC, nonsquamous non-small cell lung cancer; OS, overall survival; RCC, renal cell carcinoma.

Back to article page